Amiyotrofik Lateral Skleroz Tedavisinde Güncel Onaylanmış Hastalık Modifiye Edici Tedavi: Riluzol ve Edaravone

Öz

Motor nöron hastalığının prototipi olan Amiyotrofik lateral Skleroz (ALS) patogenezinin tam olarak anlaşılamamış olması ve hastalığın yüz güldürücü bir tedavisinin olmaması tanı sürecini hasta ve hekim için endişe verici hale getirmektedir. ALS patogenezinde yer alan süreçlerin her birine ilişkin bir çok farklı ajan denense de günümüzde belli ülkelerde onay alarak kendine yer bulmuş olan ajanlar riluzol ve edaravondur. 

Anahtar Kelimeler

• ALS,riluzol,edaravone

Abstract

The pathogenesis of the prototype of  motor neuron diseases, Amyotrophic Lateral Sclerosis (ALS), is not fully understood and the lack of a satisfactory treatment of the disease makes the diagnosis process worrying for the patient and the physician. Although many agents are used for each of the processes in ALS pathogenesis, riluzol and edaravone are the agents that have found their place in certain countries.

Keywords

• ALS,riluzol,edaravone

References

1. 1.G. Bensimon, L. Lacomblez, and V. Meininger the ALS/Riluzole Study Group.A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis.N Engl J Med 1994; 330:585-591.DOI: 10.1056/NEJM199403033300901
2. 2.Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis.Lancet. 1996 May 25;347(9013):1425-31.
3. 3.Yanagisawa N, Tashiro K, Tohgi H, et al. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi. 1997;182:851–866.
4. 4.Bensimon G, Lacomblez L, Delumeau JC, et al; Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(5):609–615.
5. 5.Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology.Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2009 Oct 13;73(15):1218-26. doi: 10.1212/WNL.0b013e3181bc0141.
6. 6.Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–375.
7. 7.Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 1997 Sep;49(3):657-9.
8. 8.Dorst J, Ludolph AC, Huebers A.Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis.Ther Adv Neurol Disord. 2017 Oct 9;11:1756285617734734. doi: 10.1177/1756285617734734. eCollection 2018.

9. 9.Watanabe T, Yuki S, Egawa M, Nishi H.Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions.J Pharmacol Exp Ther. 1994 Mar;268(3):1597-604.
10. 10.Ikeda K, Iwasaki Y, Kinoshita M. Treatment of wobbler mice with free radical scavenger.Elsevier Science,Amsterdam,Oxford,2001;1221:335-340.
11. 11.Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis(Phase II study).Amyotroph Lateral Scler. 2006 Dec;7(4):241-5.
12. 12.Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H; Edaravone ALS Study Group.Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024.
13. 13.Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H; Edaravone ALS Study Group.Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):20-31. doi: 10.1080/21678421.2017.1362000.
14. 14.Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H; Edaravone ALS Study Group.Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):40-48. doi: 10.1080/21678421.2017.1361441.
15. 15.Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H; Edaravone ALS Study Group.A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):11-19. doi: 10.1080/21678421.2017.1363780.
16. 16.Writing Group; Edaravone (MCI-186) ALS 19 Study Group.Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15.
17. 17.Hardiman O, Van Den Berg LH.Edaravone: a new treatment for ALS on the horizon?.Lancet Neurol. 2017 Jul;16(7):490-491. doi: 10.1016/S1474-4422(17)30163-1. Epub 2017 May 15.
18. 18.Turnbull J.Is edaravone harmful? Amyotroph Lateral Scler Frontotemporal Degener. 2018 Oct 29:1-6. doi: 10.1080/21678421.2018.1517179.
19. 19.Yeo CJJ,Simmons Z.Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective.Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):167-172. doi: 10.1080/21678421.2018.1425455.
20. 20.Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmøy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH.July 2017 ENCALS statement on edaravone.Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474. doi: 10.1080/21678421.2017.1369125. Epub 2017 Oct 4.